TIL
Instil Bio, Inc.
Biotechnology
Market Cap$54M
5Y Perf.-98.4%
Build Your Comparison
Side-by-side financial analysisTIL
FATE
Try popular comparisons:
Stock Comparison
TIL vs FATE
Revenue, margins, valuation, and 5-year total return — side by side.
FATE
Fate Therapeutics, Inc.
Biotechnology
Market Cap$240M
5Y Perf.-97.5%
TIL vs FATE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  TIL |  FATE |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $54M | $240M |
| Revenue (TTM) | $0.00 | $6M |
| Net Income (TTM) | $-47M | $-130M |
| Gross Margin | — | 53.8% |
| Operating Margin | — | -22.1% |
| Total Debt | $85M | $78M |
| Cash & Equiv. | $7M | $47M |
TIL vs FATE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
TIL
FATE
| Stock | Mar 21 | Jun 26 | Return |
|---|---|---|---|
| Instil Bio, Inc. (TIL) | 100 | 1.6 | -98.4% |
| Fate Therapeutics, … (FATE) | 100 | 2.5 | -97.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TIL vs FATE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: TIL leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Fate Therapeutics, Inc. is the stronger pick specifically for recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
🥇TIL emerged as the overall leader. Track its performance:
TIL
Instil Bio, Inc.
The Income Pick
TIL carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 1.55
- Lower volatility, beta 1.55, Low D/E 74.8%, current ratio 39.53x
- Beta 1.55, current ratio 39.53x
Best for: income & stability and sleep-well-at-night
FATE
Fate Therapeutics, Inc.
The Growth Play
FATE is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth -51.2%, EPS growth 29.9%, 3Y rev CAGR -59.0%
- 15.7% 10Y total return vs TIL's -98.5%
- +47.1% vs TIL's -78.9%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  TIL | 37.2% revenue growth vs FATE's -51.2% |
| Quality / Margins | TIL | -1.0% margin vs FATE's -20.6% |
| Stability / Safety | TIL | Beta 1.55 vs FATE's 1.93 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) |  FATE | +47.1% vs TIL's -78.9% |
| Efficiency (ROA) | TIL | -22.4% ROA vs FATE's -39.4%, ROIC -18.0% vs -36.5% |
TIL vs FATE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2023
TIL vs FATE — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLTILLAGGINGFATE
FATEFate Therapeutics, In…
0leads
TILInstil Bio, Inc.
2leads
6 Total Categories
CATEGORYLEADERvs FATEMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
TIL1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
TIL4/7
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
TIL leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
FATE and TIL operate at a comparable scale, with $6M and $0 in trailing revenue.
| Metric | TILInstil Bio, Inc. | FATEFate Therapeutics… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $6M |
| EBITDAEarnings before interest/tax | -$54M | -$127M |
| Net IncomeAfter-tax profit | -$47M | -$130M |
| Free Cash FlowCash after capex | -$34M | -$108M |
| Gross MarginGross profit ÷ Revenue | — | +53.8% |
| Operating MarginEBIT ÷ Revenue | — | -22.1% |
| Net MarginNet income ÷ Revenue | — | -20.6% |
| FCF MarginFCF ÷ Revenue | — | -17.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -20.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +85.6% | +18.8% |
TIL leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — TIL and FATE each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | TILInstil Bio, Inc. | FATEFate Therapeutics… |
|---|---|---|
| Market CapShares × price | $54M | $240M |
| Enterprise ValueMkt cap + debt − cash | $132M | $271M |
| Trailing P/EPrice ÷ TTM EPS | -0.74x | -1.79x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 36.13x |
| Price / BookPrice ÷ Book value/share | 0.46x | 1.18x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — TIL and FATE each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
TIL leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
TIL delivers a -39.8% return on equity — every $100 of shareholder capital generates $-40 in annual profit, vs $-59 for FATE. FATE carries lower financial leverage with a 0.38x debt-to-equity ratio, signaling a more conservative balance sheet compared to TIL's 0.75x.
| Metric | TILInstil Bio, Inc. | FATEFate Therapeutics… |
|---|---|---|
| ROE (TTM)Return on equity | -39.8% | -58.9% |
| ROA (TTM)Return on assets | -22.4% | -39.4% |
| ROICReturn on invested capital | -18.0% | -36.5% |
| ROCEReturn on capital employed | -23.3% | -43.1% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 2 |
| Debt / EquityFinancial leverage | 0.75x | 0.38x |
| Net DebtTotal debt minus cash | $79M | $31M |
| Cash & Equiv.Liquid assets | $7M | $47M |
| Total DebtShort + long-term debt | $85M | $78M |
| Interest CoverageEBIT ÷ Interest expense | -8.24x | — |
TIL leads this category, winning 4 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — TIL and FATE each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TIL five years ago would be worth $239 today (with dividends reinvested), compared to $229 for FATE. Over the past 12 months, FATE leads with a +47.1% total return vs TIL's -78.9%. The 3-year compound annual growth rate (CAGR) favors TIL at -11.1% vs FATE's -27.5% — a key indicator of consistent wealth creation.
| Metric | TILInstil Bio, Inc. | FATEFate Therapeutics… |
|---|---|---|
| YTD ReturnYear-to-date | -29.7% | +108.1% |
| 1-Year ReturnPast 12 months | -78.9% | +47.1% |
| 3-Year ReturnCumulative with dividends | -29.8% | -61.9% |
| 5-Year ReturnCumulative with dividends | -97.6% | -97.7% |
| 10-Year ReturnCumulative with dividends | -98.5% | +15.7% |
| CAGR (3Y)Annualised 3-year return | -11.1% | -27.5% |
Evenly matched — TIL and FATE each lead in 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — TIL and FATE each lead in 1 of 2 comparable metrics.
Risk & Volatility
TIL is the less volatile stock with a 1.55 beta — it tends to amplify market swings less than FATE's 1.93 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. FATE currently trades 71.5% from its 52-week high vs TIL's 20.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | TILInstil Bio, Inc. | FATEFate Therapeutics… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.55x | 1.93x |
| 52-Week HighHighest price in past year | $38.50 | $2.88 |
| 52-Week LowLowest price in past year | $5.67 | $0.91 |
| % of 52W HighCurrent price vs 52-week peak | +20.6% | +71.5% |
| RSI (14)Momentum oscillator 0–100 | 40.9 | 47.8 |
| Avg Volume (50D)Average daily shares traded | 26K | 3.2M |
Evenly matched — TIL and FATE each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | TILInstil Bio, Inc. | FATEFate Therapeutics… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $5.50 |
| # AnalystsCovering analysts | — | 31 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
TIL leads in 2 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 3 categories are tied.
Best OverallInstil Bio, Inc. (TIL)Leads 2 of 6 categories
Loading custom metrics...
TIL vs FATE: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is TIL or FATE a better buy right now?
Analysts rate Fate Therapeutics, Inc.
(FATE) a "Buy" — based on 31 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — TIL or FATE?
Over the past 5 years, Instil Bio, Inc.
(TIL) delivered a total return of -97. 6%, compared to -97. 7% for Fate Therapeutics, Inc. (FATE). Over 10 years, the gap is even starker: FATE returned +15. 7% versus TIL's -98. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — TIL or FATE?
By beta (market sensitivity over 5 years), Instil Bio, Inc.
(TIL) is the lower-risk stock at 1. 55β versus Fate Therapeutics, Inc. 's 1. 93β — meaning FATE is approximately 24% more volatile than TIL relative to the S&P 500. On balance sheet safety, Fate Therapeutics, Inc. (FATE) carries a lower debt/equity ratio of 38% versus 75% for Instil Bio, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — TIL or FATE?
On earnings-per-share growth, the picture is similar: Fate Therapeutics, Inc.
grew EPS 29. 9% year-over-year, compared to 6. 1% for Instil Bio, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — TIL or FATE?
Instil Bio, Inc.
(TIL) is the more profitable company, earning 0. 0% net margin versus -20. 5% for Fate Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TIL leads at 0. 0% versus -22. 2% for FATE. At the gross margin level — before operating expenses — TIL leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — TIL or FATE?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is TIL or FATE better for a retirement portfolio?
For long-horizon retirement investors, Instil Bio, Inc.
(TIL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Fate Therapeutics, Inc. (FATE) carries a higher beta of 1. 93 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TIL: -98. 5%, FATE: +15. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between TIL and FATE?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.